CSPG4 and neoplasm: Additionally, decitabine has been explored in conjunction with mRNA-electroporated CAR T-cells, which offer transient CAR expression to mitigate on-target/off-tumor toxicity, a critical concern given CSPG4’s low-level expression in normal tissues like the small intestine [211].